CooperCompanies stock holds a modest discount as guidance reshapes the 2026 outlook

CooperCompanies (US21664P1039) stock is trading in the mid-$70 range as of August 21, 2026, with recent market data pointing to a closing level of $76.16 in regular Nasdaq trading and a small after-hours move to $76.14 that same day. Per an equity-research overview dated August 21, 2026, this share price sits below a fair value estimate of $80.57, framing a discount of $4.41 per share or 5.5 percent for investors assessing the company’s current valuation gap. That modest disconnect between trading level and fair value comes as management has refreshed its fiscal 2026 guidance while navigating a recent GAAP loss despite ongoing revenue growth.

Guidance and latest quarter metrics

Recent commentary on CooperCompanies highlights that the company has updated its fiscal 2026 revenue guidance to US$4.3 billion, setting a clear quantitative target for the current financial year. An analysis of CooperCompanies guidance and valuation notes that this guidance arrives alongside a report of a GAAP loss in the second quarter of fiscal 2026, even as sales increased compared with the prior year. That combination suggests a tension between top-line expansion and profitability, with higher revenue not yet translating into consistent net income under GAAP for the latest reported quarter.

Additional earnings detail from a market-focused report on CooperCompanies indicates that in the latest reported quarter the company delivered adjusted earnings per share of $1.21, above a consensus figure of $1.10, showing an $0.11 upside relative to expectations for that period. Coverage of CooperCompanies latest quarterly results and guidance also points to quarterly revenue of $1.08 billion versus an analyst estimate of $1.05 billion, representing revenue growth of 7.9 percent compared with the same quarter a year earlier. In the prior-year period the company had reported earnings per share of $0.96 on a lower sales base, so the latest $1.21 figure underscores that adjusted profitability has advanced faster than revenue on a year-over-year basis even as GAAP results remain under pressure.

Analyst consensus and valuation context

Market data compiled in an August 21, 2026, forecast overview show that CooperCompanies carries a consensus rating characterized as Hold based on 17 recent analyst opinions. A consensus rating and price-target overview cites that within those 17 ratings, 3 are Sells, 6 are Holds, and 8 are Buys, illustrating divided views even as the overall stance centers on a neutral position. The same source lists a consensus price target of $81.64, which is $5.42 above the $76.22 reference price in that report and represents a projected upside of 7.11 percent from that quoted level.

That consensus positioning aligns with commentary in another institutional-ownership update, which repeats the Hold rating and the $81.64 average target while highlighting that shares recently opened trading at $76.22 in regular sessions as of August 21, 2026. An institutional-ownership update referencing CooperCompanies valuation context underlines that institutional investors have continued to adjust their positions in the stock at these price levels. When this consensus target is placed alongside the fair value estimate of $80.57 cited in the valuation-focused commentary, investors see a band of reference values several dollars above the current mid-$70 trading range, signaling that the market’s central expectations embed moderate but not dramatic upside in the coming period.

Recent share price levels and performance markers

Quote data drawn from an exchange-linked news and data page indicate that CooperCompanies stock recently traded at $76.20 as of the Cboe close on August 21, 2026, representing a daily gain of 0.08 percent for that session. A quote and short-term performance snapshot frames this closing level against a five-day change metric described as slightly negative and a year-to-date change that shows the shares down 7.10 percent from their level at the start of 2026. These metrics reinforce the picture that CooperCompanies has been lagging its own earlier-year levels even as recent sessions cluster in a narrow trading band around $76 per share.

The same quote overview places the current price context within a multi-metric snapshot that includes valuation and market-performance benchmarks for medical-technology peers. One comparative dataset, updated in late August 2026, reports that CooperCompanies stands at a share price of $61.45 in an alternative performance summary, with a 24.6 percent total return over the past twelve months and a 30.86 percent gain over a multi-year window, underscoring how different time horizons can tell contrasting stories for the same stock. A peer performance and historical return context including CooperCompanies uses these statistics in a broader comparison of medical-technology companies, highlighting that while recent months have been softer for CooperCompanies, longer-term returns remain positive.

Profitability dynamics and guidance tension

Discussion of CooperCompanies latest results emphasizes that the company’s GAAP loss in the second quarter of fiscal 2026 sits alongside solid adjusted earnings progress. The valuation-focused analysis explains that sales rose compared with the prior-year period, while the GAAP line moved into loss territory as specific expenses, accounting items, or investment-related charges weighed on reported net income. A detailed look at CooperCompanies GAAP loss and guidance update stresses that management still expects to reach US$4.3 billion in fiscal 2026 revenue, so the key question is how quickly the company can convert that anticipated sales volume into sustainable GAAP profitability.

The same coverage notes that the latest quarter’s adjusted EPS outperformance and 7.9 percent revenue growth were accompanied by a reaffirmation of fiscal 2026 EPS guidance at a range of $4.58 to $4.66, even though reported GAAP results for the quarter were negative. By maintaining this adjusted earnings guidance, management effectively signaled confidence that profit drivers such as pricing, mix, and cost controls can offset the pressures that produced the recent GAAP loss over the remainder of the fiscal year. Investors reviewing these numbers can observe that the difference between the $1.21 adjusted EPS in the latest quarter and the $0.96 reported in the same quarter a year earlier equates to an increase of $0.25 per share, demonstrating that core profitability on an adjusted basis has improved even as GAAP metrics have deteriorated.

Product focus in vision care

CooperCompanies is widely recognized for its portfolio of vision-care and specialty contact lens products, which sit at the heart of its medical technology franchise and revenue base. These products serve a range of ophthalmic indications and patient needs, from daily disposable lenses designed for convenience and hygiene to specialty lenses intended for patients with complex corneal conditions. In the latest fiscal commentary, management’s emphasis on revenue guidance and growth signals underscores that demand for these products remains a central driver of the company’s top-line trajectory, even as cost factors and investments influence current-period profitability. For investors, the performance of this product segment will continue to be a critical lens through which they interpret future quarterly updates and any adjustments to guidance.

Stock level snapshot

CooperCompanies stock most recently closed at $76.16 in regular trading on August 20, 2026, with a small after-hours change to $76.14 later that evening, according to a valuation and guidance-focused analysis dated August 21, 2026. That same analysis highlights that at this price, the shares trade at a modest discount to a fair value estimate of $80.57, implying an upside of 5.5 percent if the stock were to move in line with that benchmark. Taken together with the consensus price target of $81.64, these figures frame a valuation corridor clustered in the low $80s, providing investors with a numerical reference range against which to assess future price moves as new earnings results and guidance updates emerge.

Go deeper

Investors who want to explore the latest financial details, guidance commentary, and valuation perspectives can consult the company’s most recent earnings materials and independent analyst reports, which dissect revenue drivers, margin trends, and capital allocation decisions in depth.

Investor Relations

More on CooperCompanies stock

Fact box

Company: CooperCompanies Inc.
ISIN: US21664P1039
Ticker: COO
Exchange: Nasdaq
Market cap: Data as referenced in August 2026 commentary
Sector / Industry: Health care / Medical devices
Index membership: S&P 500